A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

Who can join: Adults 18+, are overweight.
What you take: semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 2.1 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 3Sponsor Novo Nordisk A/SDrug semaglutideClass GLP-1 RASites 46 USEnrollment target 650

What this study is for

Primary condition: Overweight. Also studied in: Obesity.

Full scientific study title: A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide.

Who can join

Age18 and upSexAny

Adults 18+, are overweight. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Male or female (sex at birth).
Age 18 years or above at the time of signing the informed consent.

Key exclusion criteria

Glycated haemoglobin (HbA1c) ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening.
History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues within 1 year before screening.

Where this trial runs

This trial has 46 sites across 16 states. Site contacts are listed for reference. They are not screening through this trial right now.

Find a site near you

California4 sites

First Valley Medical Group
Lancaster, California
Desert Oasis Healthcare
Palm Springs, California
Western University of Health Sciences
Pomona, California
Artemis Insitute for Clin Res
San Diego, California

District of Columbia1 site

Med Home Development Grp
Washington D.C., District of Columbia

Florida10 sites

Encore Medical Research LLC
Hollywood, Florida
NextPhase Research
Hollywood, Florida
Jacksonville Ctr Clin Res
Jacksonville, Florida
PharmaDev Clinical Research Institute LLC
Miami, Florida
South Broward Research LLC
Miramar, Florida
Essence MD Research
Naples, Florida
Florida Inst For Clin Res LLC
Orlando, Florida
Oviedo Medical Research, LLC
Oviedo, Florida
Palm Beach Research Center
West Palm Beach, Florida
Encore Medical Research of Weston
Weston, Florida

Georgia2 sites

Conquest Research
Atlanta, Georgia
Eastside Bariatric and Gen Surg
Snellville, Georgia

Illinois2 sites

Chicago Research Center, Inc
Chicago, Illinois
Endeavor Health
Skokie, Illinois

Indiana1 site

Midwest Inst For Clin Res
Indianapolis, Indiana

Louisiana1 site

Southern Clin Research
Zachary, Louisiana

Missouri1 site

Amicis Centers of Clinical Research
St Louis, Missouri

New York2 sites

Ichor Research
Syracuse, New York
Southgate Medical Group, LLP
West Seneca, New York

North Carolina3 sites

University of North Carolina
Chapel Hill, North Carolina
PharmQuest Life Sciences LLC
Greensboro, North Carolina
Piedmont Healthcare/Research
Statesville, North Carolina

North Dakota1 site

Lillestol Research LLC
Fargo, North Dakota

Pennsylvania1 site

Geisinger Clinic
Danville, Pennsylvania

South Carolina3 sites

Medical University Of South Carolina
Charleston, South Carolina
Hillcrest Clinical Research
Simpsonville, South Carolina
Spartanburg Medical Research
Spartanburg, South Carolina

Texas10 sites

Amarillo Med Spec LLP
Amarillo, Texas
Texas Diabetes & Endocrinology
Austin, Texas
Pinnacle Clinical Research
Brownsville, Texas
Osvaldo A. Brusco MD
Corpus Christi, Texas
UT Southwestern Med Center
Dallas, Texas
Epic Medical Research
DeSoto, Texas
Houston Research Institute
Houston, Texas
The Endocrine Center
Houston, Texas
Sleep Therapy Research Center
San Antonio, Texas
Olympus Clinical Research
Sugar Land, Texas

Virginia2 sites

National Clin Res Inc.
Richmond, Virginia
Gastroent Consult of SW VA
Roanoke, Virginia

Washington2 sites

Rainier Clin Res Ctr Inc
Renton, Washington
Seattle Clinical Research Center
Seattle, Washington

Follow this trial

We email you if NCT07668414 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Scheduled start: September 22, 2026. Expected completion: October 10, 2028. Last updated on ClinicalTrials.gov: June 25, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.